Cargando…

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer

Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype presents with an aggressive clinical course, heightened metastatic potential and the poorest short-term prognosis. TNBC doe...

Descripción completa

Detalles Bibliográficos
Autores principales: Poddar, Arpita, Rao, Sushma R., Prithviraj, Prashanth, Kannourakis, George, Jayachandran, Aparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601266/
https://www.ncbi.nlm.nih.gov/pubmed/36290817
http://dx.doi.org/10.3390/curroncol29100540
_version_ 1784817018136952832
author Poddar, Arpita
Rao, Sushma R.
Prithviraj, Prashanth
Kannourakis, George
Jayachandran, Aparna
author_facet Poddar, Arpita
Rao, Sushma R.
Prithviraj, Prashanth
Kannourakis, George
Jayachandran, Aparna
author_sort Poddar, Arpita
collection PubMed
description Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype presents with an aggressive clinical course, heightened metastatic potential and the poorest short-term prognosis. TNBC does not respond to hormonal therapy, only partially responds to radio- and chemotherapy, and has limited targeted therapy options, thus underlining the critical need for better therapeutic treatments. Although immunotherapy based on immune checkpoint inhibition is emerging as a promising treatment option for TNBC patients, activation of cellular plasticity programs such as metabolic reprogramming (MR) and epithelial-to-mesenchymal transition (EMT) causes immunotherapy to fail. In this report, we review the role of MR and EMT in immune checkpoint dysregulation in TNBCs and specifically shed light on development of novel combination treatment modalities for this challenging disease. We highlight the clinical relevance of crosstalk between MR, EMT, and immune checkpoints in TNBCs.
format Online
Article
Text
id pubmed-9601266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96012662022-10-27 Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer Poddar, Arpita Rao, Sushma R. Prithviraj, Prashanth Kannourakis, George Jayachandran, Aparna Curr Oncol Review Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype presents with an aggressive clinical course, heightened metastatic potential and the poorest short-term prognosis. TNBC does not respond to hormonal therapy, only partially responds to radio- and chemotherapy, and has limited targeted therapy options, thus underlining the critical need for better therapeutic treatments. Although immunotherapy based on immune checkpoint inhibition is emerging as a promising treatment option for TNBC patients, activation of cellular plasticity programs such as metabolic reprogramming (MR) and epithelial-to-mesenchymal transition (EMT) causes immunotherapy to fail. In this report, we review the role of MR and EMT in immune checkpoint dysregulation in TNBCs and specifically shed light on development of novel combination treatment modalities for this challenging disease. We highlight the clinical relevance of crosstalk between MR, EMT, and immune checkpoints in TNBCs. MDPI 2022-09-23 /pmc/articles/PMC9601266/ /pubmed/36290817 http://dx.doi.org/10.3390/curroncol29100540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Poddar, Arpita
Rao, Sushma R.
Prithviraj, Prashanth
Kannourakis, George
Jayachandran, Aparna
Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
title Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
title_full Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
title_fullStr Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
title_full_unstemmed Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
title_short Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
title_sort crosstalk between immune checkpoint modulators, metabolic reprogramming and cellular plasticity in triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601266/
https://www.ncbi.nlm.nih.gov/pubmed/36290817
http://dx.doi.org/10.3390/curroncol29100540
work_keys_str_mv AT poddararpita crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer
AT raosushmar crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer
AT prithvirajprashanth crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer
AT kannourakisgeorge crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer
AT jayachandranaparna crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer